Klijn JG - Search Results

1

Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects.

Alexieva-Figusch J, Blankenstein MA, Hop WC, Klijn JG, Lamberts SW, de Jong FH, Docter R, Adlercreutz H, van Gilse HA. Alexieva-Figusch J, et al. Among authors: klijn jg. Eur J Cancer Clin Oncol. 1984 Jan;20(1):33-40. doi: 10.1016/0277-5379(84)90031-2. Eur J Cancer Clin Oncol. 1984. PMID: 6363095 Clinical Trial.

2

LHRH-agonist treatment in metastatic prostate carcinoma.

Klijn JG, de Jong FH, Lamberts SW, Blankenstein MA. Klijn JG, et al. Eur J Cancer Clin Oncol. 1984 Apr;20(4):483-93. doi: 10.1016/0277-5379(84)90233-5. Eur J Cancer Clin Oncol. 1984. PMID: 6426968

3

Antiprogestins, a new form of endocrine therapy for human breast cancer.

Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J. Klijn JG, et al. Cancer Res. 1989 Jun 1;49(11):2851-6. Cancer Res. 1989. PMID: 2720645

4

Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.

Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, Klijn JG. Bakker GH, et al. Among authors: klijn jg. Cancer Treat Rep. 1987 Nov;71(11):1021-7. Cancer Treat Rep. 1987. PMID: 3119199

5

The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.

Alexieva-Figusch J, Van Putten WL, Blankenstein MA, Blonk-Van Der Wijst J, Klijn JG. Alexieva-Figusch J, et al. Among authors: klijn jg. Cancer. 1988 Feb 15;61(4):758-68. doi: 10.1002/1097-0142(19880215)61:4<758::aid-cncr2820610421>3.0.co;2-t. Cancer. 1988. PMID: 3338038

6

LHRH-agonist treatment in clinical and experimental human breast cancer.

Klijn JG, de Jong FH, Lamberts SW, Blankenstein MA. Klijn JG, et al. J Steroid Biochem. 1985 Nov;23(5B):867-73. doi: 10.1016/s0022-4731(85)80029-7. J Steroid Biochem. 1985. PMID: 3935869 Clinical Trial.

7

Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells.

Blankenstein MA, Henkelman MS, Klijn JG. Blankenstein MA, et al. Among authors: klijn jg. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1493-9. doi: 10.1016/0277-5379(85)90244-5. Eur J Cancer Clin Oncol. 1985. PMID: 3938397

8

Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study).

Alexieva-Figusch J, Van Putten WL, van Gilse HA, Blonk-vd Wijst J, Klijn JG. Alexieva-Figusch J, et al. Among authors: klijn jg. Med Oncol Tumor Pharmacother. 1985;2(2):69-75. doi: 10.1007/BF02934851. Med Oncol Tumor Pharmacother. 1985. PMID: 4058078

9

Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.

Klijn JG, de Jong FH. Klijn JG, et al. Lancet. 1982 May 29;1(8283):1213-6. doi: 10.1016/s0140-6736(82)92339-x. Lancet. 1982. PMID: 6122975

10

Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Klijn JG, de Jong FH, Blankenstein MA, Docter R, Alexieva-Figusch J, Blonk-van der Wijst J, Lamberts SW. Klijn JG, et al. Breast Cancer Res Treat. 1984;4(3):209-20. doi: 10.1007/BF01806487. Breast Cancer Res Treat. 1984. PMID: 6435703 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters